Cambridge biopharma announces research agreement with UMass Medical School
Cambridge-based biopharmaceutical company Enumeral Biomedical Holdings has announced a research study agreement with the University of Massachusetts Medical School to aid the company in developing new cancer therapies.
Under the agreement, which also includes UMass Memorial Health Care as the medical school’s clinical partner, UMass Medical School (UMMS) will provide Enumeral with tissue and blood samples from melanoma patients being treated with the drug Yervoy, a drug made by Bristol-Myers Squibb.
Enumeral will fund these tissue collection activities and the company will have access to the samples for research use in in-vitro studies using its platform, which is designed to identify promising new drugs relevant to cancer, infectious and inflammatory diseases, according to the Enumeral’s website.
Enumeral scientists will apply the company’s proprietary technology to analyze single immune cells within patient samples. The study will be conducted under the direction of Dr. William Walsh, clinical associate professor at UMass Medical School and the study’s principal investigator.
“We are very excited to partner with the University of Massachusetts Medical School and UMass Memorial Health Care in this research study. Information our platform generates … could enable us to generate insights into which immunotherapeutic strategies may be successful in patients that are not well-treated by currently marketed drugs,” said Enumeral CEO Arthur H. Tinkelenberg, in a statement.
WBJ Web Partners
Most Recent
Most Recent
0 Comments